NCT03532802View on ClinicalTrials.gov

The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

September 1, 2020

Study Completion Date

September 1, 2020

Conditions
Hypertrophic Cardiomyopathy
Interventions
DRUG

Metoprolol Succinate

"1. week: uptitration with 50 mg capsules per day, until maximum dosage of 150 mg´s/day.~2. week: steady state treatment with the maximum tolerated dose of the 1.week."

DRUG

Placebo oral capsule

"1. week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~2. week: steady state treatment with the maximum tolerated dose of the 1. week"

Trial Locations (1)

8200

Aarhus University Hospital, Department of Cardiology, Aarhus N

All Listed Sponsors
lead

Steen Hvitfeldt Poulsen

OTHER

NCT03532802 - The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy. | Biotech Hunter | Biotech Hunter